Published in Ned Tijdschr Geneeskd on September 02, 1989
Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol (2001) 3.94
Sentinel lymph node procedure is highly accurate in squamous cell carcinoma of the vulva. J Clin Oncol (2000) 3.20
Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer (2000) 2.86
Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol (2000) 2.04
Incidence and effect on survival of abdominal wall metastases at trocar or puncture sites following laparoscopy or paracentesis in women with ovarian cancer. Gynecol Oncol (1996) 1.59
Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet (2001) 1.56
Leiomyomatosis peritonealis disseminata: does malignant transformation occur? A literature review. Gynecol Oncol (1999) 1.55
Clinical and genetic evaluation of thirty ovarian cancer families. Am J Obstet Gynecol (1998) 1.49
Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer (2001) 1.15
A quantitative polymerase chain reaction-enzyme immunoassay for accurate measurements of human papillomavirus type 16 DNA levels in cervical scrapings. Br J Cancer (1999) 1.07
HPV 16 infection and progression of cervical intra-epithelial neoplasia: analysis of HLA polymorphism and HPV 16 E6 sequence variants. Int J Cancer (1998) 1.06
Tubal ligation and risk of ovarian cancer. Lancet (2001) 1.04
Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study. Cancer Res (1998) 1.04
Diathermy loop excision in the management of cervical intraepithelial neoplasia: diagnosis and treatment in one procedure. Am J Obstet Gynecol (1992) 1.03
Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int J Cancer (2000) 1.02
Prospective multicenter evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasias. Am J Surg Pathol (2001) 1.01
Human MUC1 mucin: a multifaceted glycoprotein. Int J Biol Markers (2001) 1.00
Cell cycle-related proteins p21 and bcl-2: markers of differentiation in the human fallopian tube. Histopathology (2001) 0.99
Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. Eur J Nucl Med (1998) 0.94
Analysis of human papillomavirus type 16 E6 variants in relation to p53 codon 72 polymorphism genotypes in cervical carcinogenesis. J Gen Virol (2000) 0.94
Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia. J Gen Virol (1999) 0.94
Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes. Cancer Lett (1997) 0.94
Development and validation of a computerized cytomorphometric method to assess the maturation of vaginal epithelial cells. Cytometry (1999) 0.93
Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. J Natl Cancer Inst (1997) 0.93
Ovarian abscess during pregnancy mimicking a leiomyoma of the uterus: a complication of transvaginal ultrasound-guided oocyte aspiration. J Assist Reprod Genet (1996) 0.91
Survival analysis in familial ovarian cancer, a case control study. Eur J Obstet Gynecol Reprod Biol (2001) 0.89
Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer. J Nucl Med (2000) 0.88
Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test. Br J Cancer (2010) 0.88
Differences in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix. Eur J Cancer (1999) 0.88
Immunoscintigraphy of ovarian cancer with indium-111-labeled OV-TL 3 F(ab')2 monoclonal antibody. J Nucl Med (1990) 0.86
Type II secretory phospholipase A2 binds to ischemic flip-flopped cardiomyocytes and subsequently induces cell death. Am J Physiol Heart Circ Physiol (2003) 0.86
Improvement of clinical staging in cervical cancer with serum squamous cell carcinoma antigen and CA 125 determinations. Gynecol Oncol (1997) 0.85
Differences between hereditary and sporadic ovarian cancer. Eur J Obstet Gynecol Reprod Biol (1999) 0.84
Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: a phase I study. Cancer (1997) 0.84
Ovarian cancer in female-to-male transsexuals: report of two cases. Gynecol Oncol (2000) 0.83
T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection. J Gen Virol (1996) 0.83
Mesodermal mixed tumor. Diagnosis by analysis of intermediate filament proteins. Am J Surg Pathol (1983) 0.83
Comparative genomic hybridization of microdissected familial ovarian carcinoma: two deleted regions on chromosome 15q not previously identified in sporadic ovarian carcinoma. Lab Invest (2001) 0.83
Kinetics and biodistribution in relation to tumour detection with 111In-labelled OV-TL 3 F(ab')2 in patients with ovarian cancer. Nucl Med Commun (1991) 0.83
Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p. Int J Cancer (2001) 0.82
Analysis of IgG reactivity against Human Papillomavirus type-16 E7 in patients with cervical intraepithelial neoplasia indicates an association with clearance of viral infection: results of a prospective study. Int J Cancer (1996) 0.81
Endometrial cancer in four sisters: report of a kindred with presumed cancer family syndrome. Gynecol Oncol (1994) 0.81
Biodistribution of 111In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01. Cancer Immunol Immunother (1998) 0.81
Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab')2 in ovarian carcinoma patients. Int J Cancer (1996) 0.81
Mucin-like carcinoma-associated antigen serum levels in patients with adenocarcinomas originating from ovary, breast and colon. Gynecol Obstet Invest (1996) 0.80
Ovarian cancer incidence (1989-1991) and mortality (1954-1993) in The Netherlands. Obstet Gynecol (1996) 0.80
Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix. Int J Cancer (1991) 0.80
Applications of a human tumour clonogenic cell culture system in gynaecological oncology: review and personal experience. Eur J Obstet Gynecol Reprod Biol (1984) 0.80
Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia. Eur J Cancer (2012) 0.80
Expression of CD3-zeta on T-cells in primary cervical carcinoma and in metastasis-positive and -negative pelvic lymph nodes. Br J Cancer (1999) 0.80
The role of deoxyribonucleic acid image cytometric and interphase cytogenetic analyses in the differential diagnosis, prognosis, and clinical follow-up of hydatidiform moles. A report from the Central Molar Registration in The Netherlands. Am J Obstet Gynecol (1997) 0.79
Cell DNA content--correlation with clonogenicity in the human tumour cloning system (HTCS). Int J Cancer (1985) 0.78
Biodistribution of (111)indium-labeled engineered human antibody CTMO1 in ovarian cancer patients: influence of protein dose. Cancer Res (1996) 0.78
Detection and localization of ovarian cancer with radiolabeled monoclonal antibodies. Eur J Obstet Gynecol Reprod Biol (1991) 0.77
Digital color imaging colposcopy: a matter of choice. Eur J Obstet Gynecol Reprod Biol (1998) 0.77
Specific and nonspecific immunoassays to detect HAMA after administration of indium-111-labeled OV-TL 3 F(ab')2 monoclonal antibody to patients with ovarian cancer. J Nucl Med (1992) 0.77
Clinical applications of monoclonal antibodies against ovarian cancer-associated antigens. Eur J Obstet Gynecol Reprod Biol (1988) 0.77
Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease. Ann Oncol (1997) 0.76
Tumour detection and localization using 99Tcm-labelled OV-TL 3 Fab' in patients suspected of ovarian cancer. Nucl Med Commun (1992) 0.76
Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer. Eur J Obstet Gynecol Reprod Biol (1999) 0.76
Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors. Am J Clin Oncol (2001) 0.76
[Treatment of patients with trophoblastic tumor in the Academic Medical Center: 31 patients in 10 years, 1983-1992]. Ned Tijdschr Geneeskd (1995) 0.75
Time course of ovarian tumour growth in soft agar culture. Br J Cancer (1985) 0.75
Differential diagnosis and causes of nonimmunological hydrops fetalis: a review. Obstet Gynecol Surv (1991) 0.75
[Morbidity and results of 100 radical hysterectomies performed in an oncology center]. Ned Tijdschr Geneeskd (1992) 0.75
Analytical and clinical performance of improved Abbott IMx CA 125 assay: comparison with Abbott CA 125 RIA. Clin Chem (1995) 0.75
[The lost IUD: don't look too far for it]. Ned Tijdschr Geneeskd (1985) 0.75
Humoral anti-OV-TL 3 response after the intravenous administration of radiolabelled Fab' or F(ab')2 fragments in ovarian cancer patients. Nucl Med Commun (1995) 0.75
Successful treatment of an advanced interstitial pregnancy by sequential systemic and local administration of methotrexate. Hum Reprod (1995) 0.75
[Refocusing on the gynecological and obstetrical consequences of intrauterine exposure to diethylstilbestrol (DES)]. Ned Tijdschr Geneeskd (1991) 0.75
Results of cyclophosphamide and cisplatin combination chemotherapy in patients with ovarian carcinoma. Eur J Gynaecol Oncol (1992) 0.75
Prospects and applications of monoclonal antibodies in gynecological oncology. Eur J Obstet Gynecol Reprod Biol (1985) 0.75
Cis-platin in combination with low dose adriamycin and cyclophosphamide in advanced ovarian carcinoma. Eur J Gynaecol Oncol (1985) 0.75
Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study. Anticancer Res (2000) 0.75
An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinoma. Br J Obstet Gynaecol (1999) 0.75
The management of granulosa cell tumor of the ovary--a case history. Ann Oncol (1996) 0.75
Automated counting of human tumour colonies in the Courtenay-Mills assay system. Cell Biol Int Rep (1985) 0.75
Real-time ultrasound as an adjunct in the operative management of hydatidiform mole. Am J Obstet Gynecol (1981) 0.75
Biodistribution of iodine-125 and indium-111 labeled OV-TL 3 intact antibodies and F(ab')2 fragments in tumor-bearing athymic mice. Anticancer Res (1992) 0.75
[Favorable results of paclitaxel (Taxol) in patients with ovary carcinoma pretreated with platinum]. Ned Tijdschr Geneeskd (1995) 0.75
Identification of patients with persistent trophoblastic disease by means of a normal human chorionic gonadotropin regression curve. Am J Obstet Gynecol (1993) 0.75
Persistent gestational trophoblastic disease: DNA image cytometry and interphase cytogenetics have limited predictive value. Mod Pathol (1996) 0.75